Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Drax lets proposed HEIT acquisition lapse

(Sharecast News) - Drax Group's proposed acquisition of Harmony Energy Income Trust (HEIT) lapsed on Friday, after key conditions were not met by the agreed deadline. The bid had been led by Drax BESS Holdco, a wholly owned subsidiary of the FTSE 250-listed Drax Group, and was to be implemented via a court-sanctioned scheme of arrangement under the Companies Act.

A sterling-denominated cash offer was first agreed and announced in March, with the transaction contingent on a number of conditions, including the convening of a court meeting by 29 May, a date referred to in the offer terms as the 'mini long stop date'.

No extension to the deadline was agreed between Drax and HEIT.

As the court meeting condition was not satisfied in time, Drax said it had exercised its right to invoke the long stop provision, causing the scheme to lapse with immediate effect.

The lapse meant that the proposed acquisition of HEIT would no longer proceed under the terms previously announced.

Drax had published a full scheme document in April setting out the terms of the offer and the regulatory process required for completion.

At 0922 BST, shares in Drax Group were up 1.95% at 654.5p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.